KROS250117C17500
- 1.50
- -0.05-3.23%
Keros Therapeutics Newsroom
Keros Therapeutics Is Maintained at Buy by Truist Securities
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43
Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating
Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63
Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63
Keros Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40
Keros Therapeutics Cut to Neutral From Buy by Guggenheim
Express News | Keros Therapeutics Inc : Piper Sandler Cuts Target Price to $40 From $105
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
Guggenheim Downgrades Keros Therapeutics(KROS.US) to Hold Rating
Keros Therapeutics Price Target Raised to $28 From $11 at Wells Fargo
Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank
Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84
Truist Financial Issues a Buy Rating on Keros Therapeutics (KROS)